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Brief Communication
Generation of Functional Myocytes from Equine
Induced Pluripotent Stem Cells
Karin R. Amilon,1 Yennifer Cortes-Araya,1 Benjamin Moore,1 Seungmee Lee,1 Simon Lillico,1
Amandine Breton,1 Cristina L. Esteves,1 and F. Xavier Donadeu1,2
Abstract
Induced pluripotent stem cells (iPSCs) have revolutionized human biomedicine through their use in disease
modeling and therapy. In comparison, little progress has been made toward the application of iPSCs in veterinary
species. In that regard, skeletal myocytes from iPSCs would have great potential for understanding muscle
function and disease in the equine athlete. In this study, we generated skeletal myotubes by transducing equine
iPSC-derived mesenchymal derivatives with an inducible lentiviral vector coding for the human sequence of the
myogenic factor, MyoD. Myosin heavy chain-positive myotubes generated from two different iPSC lines were
compared to myotubes from adult equine skeletal muscle progenitor cells (MPCs). iPSC myotubes had a smaller
mean area than MPC myotubes (£2-fold). In addition, quantitative polymerase chain reaction analyses showed
that iPSC myotubes expressed MYH2 and MYH3 isoforms (at similar or lower levels than MPC myotubes), but
they did not express the mature muscle isoform, MYH1. Compared to MPC myotubes, iPSC myotubes expressed
reduced levels of the myogenic factors, MYOD1 and MYF6, but did not express MYF5. Finally, iPSC myotubes
responded to KCl-induced membrane depolarization by releasing calcium and did so in a manner similar to MPC
myotubes. In conclusion, this is the first study to report the generation of functional myocytes from equine iPSCs.
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Introduction
Despite the importance of healthy skeletal mus-cle for the equine athlete, little is known about the
mechanisms underpinning its development and disease mech-
anisms. A particularly important issue for the horse industry is
the relatively high incidence of equine-inherited myopathies,
including polysaccharide storage myopathy (PSSM1), hy-
perkalemic periodic paralysis (HYPP), and recurrent exertional
rhabdomyolysis, a consequence of historic selection for desired
performance traits in some horse breeds such as the Quarter
Horse (Mickelson and Valberg, 2015). Some of those myo-
pathies also occur in other species, including humans.
Given the difficulties associated with performing studies
in vivo, progress toward understanding their pathogenesis
would be significantly facilitated by the availability of robust
in vitro disease models allowing functional testing of already
identified candidate gene mutations, for example, in the case of
PSSM1 and HYPP. Significant effort has already been put into
developing such models using primary (Baquero-Perez et al.,
2012) or immortalized (Naylor and Piercy, 2015) muscle cells
or muscle-like cells generated through forced transdifferentia-
tion of skin cells (Fernandez-Fuente et al., 2008). However, the
applicability of thesemodels to study disease is limited because
they require biopsy sampling of patient tissues, which is not
always possible, and the cells have limited lifespan and/or a
restricted ability to replicate the native myocyte phenotype
in vitro, thus precluding meaningful gene function analyses.
In that regard, given their ability to proliferate indefinitely
in vitro, high developmental plasticity and amenability to robust
genetic manipulation, using novel gene editing technologies,
induced pluripotent stem cells (iPSCs) offer a unique tool for
understanding the effects of disease-causing genetic mutations
and for testing novel therapeutic targets through what has been
called ‘‘disease in a dish’’ (Hockemeyer and Jaenisch, 2016).
iPSCs are already being used for modeling human skel-
etal muscle disease, for example, Duchenne muscular dys-
trophy and type 2 diabetes (Choi et al., 2016; Iovino et al.,
2016), and functional myogenic precursors have been gen-
erated that can efficiently engraft and promote muscle
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regeneration in animal models (Darabi et al., 2012). Func-
tional muscle cells have been generated from human or
rodent iPSCs/embryonic stem cells (ESC) by forced ex-
pression of ectopic myogenic genes, primarily Pax7 or
MyoD (Chal and Pourquie, 2017), or, more recently, using
chemical approaches that aim to replicate muscle develop-
ment in the embryo to produce genetically unmodified cells
that could be ideally used for developmental muscle studies
(Chal et al., 2016; Xu et al., 2013).
Compared to humans, the availability of iPSCs (and spe-
cially ESCs) from horses is limited, as is the number of studies
reporting their differentiation into functional cell types (Do-
nadeu, 2014). A previous study showed the generation of
myosin heavy chain (MyHC)-positive myotubes from equine
skeletal muscle cell-derived iPSCs (Quattrocelli et al., 2016),
whereas another reported formation of muscle fibers after
transplantation of equine adipose stem cell-derived iPSCs into
injured skeletal muscle of mice (Lee et al., 2016). In the
present study, we took a step further by generating functional
myocytes from equine iPSCs and comparing their character-
istics with those of myocytes produced from adult equine
skeletal muscle precursors.
Materials and Methods
Cell derivation and culture
Two different iPSC lines (H and U) derived from equine
fibroblasts in our laboratory (Breton et al., 2013) were used in
this study. iPSCs were maintained on Matrigel (BD Bios-
ciences) in conditioned medium generated from inactivated
equine fetal fibroblasts (Sharma et al., 2014) comprising
knockout-DMEM (Dulbecco’s modified Eagle’s medium)
(Gibco), 20% knockout serum replacement (Gibco), 0.1mM
b-mercaptoethanol, 0.1mM nonessential amino acids (Gibco),
2mM L-glutamine (Gibco), 1000U/mL leukemia inhibitory
factor (LIF; Sigma-Aldrich), and 8ng/mL human basic fibro-
blast growth factor (bFGF; Sigma-Aldrich). Cells were in all
cases cultured at 37C in a humidified atmosphere with 5%CO2
and unless specified, medium was replaced every 1–2 days.
Skeletal muscle was obtained postmortem from an adult horse
euthanized for unrelated reasons at the Royal (Dick) School of
Veterinary Studies, University of Edinburgh. The tissue was
cut into small pieces (*3 cm2), washed in phosphate-buffered
saline (PBS), and minced using sterile forceps and scissors
before digestion with 1% Protease in high-glucose DMEM
(Sigma-Aldrich) at 37C for 1 hour, with shaking at 100 rpm.
Digested tissue was then centrifuged at 400 g for 5 minutes,
and the resulting tissue/cell pellet was suspended in high-glu-
cose DMEM containing 10% fetal bovine serum (FBS; Gibco)
and 1% penicillin–streptomycin (PS; Gibco), and passed vig-
orously through a 10mL pipette about 20 times before allowed
to settle. The supernatant was transferred to a fresh tube, and the
remaining pellet was passed repeatedly through a 5mL pipette
before another supernatant was collected. The pooled superna-
tantswere filtered through a 40lmcell strainer and subsequently
centrifuged at 1000 g for 10 minutes, after which the resulting
cell pellet was plated onto 0.2% gelatin (Sigma-Aldrich) in
high-glucose DMEM containing 10% FBS and 1% PS.
Cells were cultured for three to four passages before in-
duced to differentiate using an adaptation of the protocol by
Chen et al. (2015). In brief, cells (2· 103/cm2) were seeded
on collagen (Sigma-Aldrich) in skeletal proliferation medium
containing high-glucose DMEM, 10% FBS, 10% horse serum
(HS; Gibco), 1% chicken embryo extract (CEE, CE-650-J;
Seralab), and 1% PS. When 80% confluent, cells were tryp-
sinized, counted, and again seeded at the same density on
collagen and cultured in the same media until 80% confluent,
after which cells were lifted and seeded at 2· 104 cells/cm2
on collagen in skeletal differentiation medium containing
high glucose-DMEM, 1% FBS, 1% HS, 0.1% CEE, and 1%
PS. Cells were differentiated for 7 days before samples were
collected for immunocytochemistry and mRNA analysis.
Chemically induced iPSC differentiation
Equine iPSCs were differentiated as described for human
iPSCs by Chal et al. (2016). In brief, cells were seeded in
Matrigel-coated 12-well plates (70,000 cells/well) in
mTeSR1 media (Stem Cell Technologies [STC]) on day 1,
after which they were incubated in DMEM containing ITS
(1/100; Gibco), GSK-inhibitor (CHIRON, 3lM; STC), and
ALK inhibitor (LDN-193189, 0.5lM; Stemgent) between
days 2 and 5, with bFGF (20 ng/mL) added for the last 2 days.
Cells were then changed to DMEM containing HGF
(10 ng/mL; Biolegend), IGF1 (2 ng/mL; Sigma-Aldrich),
bFGF, and LDN-193189 until day 7 and then placed in
DMEM with knockout serum replacement and IGF-1 to
which bFGF was added on day 12, under which cells were
maintained up to at least day 30. Samples were collected
for immunochemistry and quantitative polymerase chain
reaction (qPCR) analyses as described below.
iPSC differentiation using MyoD lentivirus
Lentiviral particles were generated by cotransfecting
HEK293T cells with LV-TRE-WT human MyoD-T2A-dsRe-
dExpress2 obtained from Addgene (plasmid 60628) (Kabadi
et al., 2015), the packaging plasmid psPAX2, and VSVG-
plasmid using FuGENE HD Transfection Reagent (Pro-
mega). The MyoD-coding plasmid contains a puromycin
resistance gene sequence. Cells were incubated for 48 hours,
after which the supernatant was harvested, passed through a
0.45lm filter and concentrated by ultracentrifugation. The
final virus suspension was stored as single use aliquots at
-80C. The viral titer was determined by transducing HT1080
cells with serial dilutions of the viral stock solution for 24
hours, followed by Puromycin (1 lg/mL; Sigma-Aldrich)
selection and counting of positive transductants. Viral trans-
ducing units were calculated to be 1.7· 106/mL.
Equine iPSCs were trypsinized and seeded at 15,000
cells/cm2 in iPSC conditions (see above) before they were
transduced as described below. Alternatively, before trans-
duction, iPSCs were trypsinized and seeded onto 0.2%
gelatin in high-glucose DMEM containing 10% FBS and
1% PS to allow spontaneous differentiation, and 14 days
later they were trypsinized and seeded at a density of 5000
cells/cm2 and allowed to adhere overnight.
In all cases, cells were then transduced with 5lg/mL
polybrene (Santa Cruz Biotechnology) and lentivirus at mul-
tiplicities of infection between 2 and 6 for 24 hours, after which
the cells were washed with PBS and refreshed with culture
medium containing 1–2lg/mL puromycin for selection and
expansion of positive transductants. Before transduction, a kill
curve was performed to determine optimal Puromycin con-
centration for each cell type.
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Puromycin-resistant cells were seeded in 12-well plates
(40,000/well) in DMEM high glucose containing 10% FBS
and 1% PS. The following day, doxycycline (Sigma-
Aldrich) was added to a concentration of 3 lg/mL, and
cells were differentiated for 7 days as described above for
skeletal muscle cells, after which samples were collected
for immunocytochemistry, qPCR, or calcium analyses.
Immunocytochemistry
Cells were fixed and permeabilized in ice-cold metha-
nol:acetone (50:50) solution for 10 minutes at room tem-
perature, followed by washing with PBS for 3· 5 minutes
and incubated with protein block solution (Springbio) for 1
hour at room temperature. Cells were stained with anti-
MyHC antibody (10lg/mL, #MF20 MAB4470; R&D Sys-
tems) in antibody diluent reagent (Invitrogen) at 4C over-
night. Cells were washed with PBS to remove any unbound
antibody and incubated with AF488-conjugated goat anti-
mouse IgG (A11029; Invitrogen) for 1 hour at room tem-
perature and kept in the dark. Cells were washed as before
and mounted in Fluoroshield with DAPI (Sigma-Aldrich),
sealed with a coverslip and examined using a Zeiss Axiovert
25 inverted fluorescent microscope.
Pictures were taken using a Zeiss Axiocam 503 high-
resolution color camera/Zen software. Myotube area and num-
ber of myonuclei were determined from MYH-stained pictures
using ImageJ software; for each cell type, mean values were
taken from four myotubes analyzed from each of four pictures.
Quantitative polymerase chain reaction
Cells were harvested into TRIzol (Thermo Fisher Scientific),
and RNA was extracted according to the manufacturer’s pro-
tocol. Total RNA was quantified by Nanodrop (Thermo Sci-
entific), and 1lg was reverse transcribed using Superscript III
(Thermo Fisher scientific). qPCR was performed using Sensi-
FAST SYBR Lo-ROX Kit (Bioline) in a MX3005P system
(Stratagene) and data analyzed with MxPro Software. Ex-
pression for each gene was determined using standard curves
prepared from skeletal muscle or pooled samples and normal-
ization to the expression of 18S within each sample. Primers
used are listed in Table 1.
Calcium assay
Fluo-4 Direct Calcium Assay Kit (Invitrogen) was used
according to the manufacturer’s protocol to fluorescently
label myotubes to monitor Ca2+ release in response to
membrane depolarization with 75mM KCl. Myotubes were
examined under a Zeiss Axiovert 25 inverted fluorescent
microscope and pictures were taken before and 1 minute
after addition of KCl using a Zeiss Axiocam 503 high-
resolution color camera with Zen software. Average Fluo-4
intensity was calculated from images from five to six myo-
tubes analyzed using ImageJ.
Statistical analyses
Data normality was assessed by Kolmogorov–Smirnoff test,
and data were log-transformed before analyses if needed. Data
were then analyzed using the GLM (generalized linear model)
procedure by one-way ANOVA followed by Tukey’s pairwise
comparison tests. In all cases, statistical significance was
considered at p<0.05.
Results and Discussion
Generation of myotubes from iPSCs
We first tested a directed differentiation approach success-
fully used to generate functional skeletal muscle from mouse
and human PSCs and that recapitulates paraxial mesoderm
specification and differentiation bymanipulating key signaling
pathways such asWNT andBMP (Chal et al., 2016). Although
cells adopted an elongated morphology under these condi-
tions, very few multinucleated structures were observed dur-
ing the 50-day differentiation protocol, and no expression of
progenitor (MYOD1,MYF5) or differentiated (MYH1,MYH2,
MYH3) muscle cell transcripts was detected by qPCR in these
cultures, indicating that these conditions are not optimum for
promoting myogenic differentiation of equine iPSCs.
We then decided to use a transgenic approach involving
expression of inducible MyoD. To that end, we transduced
iPSCs with LV-TRE-WT human MyoD-T2A-dsRedEx-
press2. Although some cells exhibited red fluorescence after
addition of doxycycline, there were no signs of myogenesis
after puromycin-selected cells were cultured in differentia-
tion media. This could be partly attributed to low efficiency
of iPSC transfection, as indicated by the presence of only a
few red fluorescence cells. Moreover, previous studies in
other species (Albini et al., 2013; Goudenege et al., 2012)
have shown the requirement for pluripotent cells to transi-
tion to a mesodermal stage before they become epigeneti-
cally competent to initiate myogenesis in response to MyoD
(Albini et al., 2013).
Therefore, we decided to introduce a differentiation step to
generate mesenchymal-like cells, which we reasoned would
be both easier to transduce and already primed for myo-
genesis. To achieve this, iPSCs (Fig. 1A) were placed in
DMEM-containing 10% FBS for 14 days in the absence of
Table 1. List of Primers Used for Quantitative Polymerase Chain Reaction Analyses
Gene Forward primer (5¢-3¢) Reverse primer (5¢-3¢)
18S GCTGGCACCAGACTTG GGGGAATCAGGGTTCG
MYH1 CACTTCAAGGCCGCATCTCTA AACTCATGGCTGCGGGTTAT
MYH2 GGAGGCTGAGGAACAATCCA CTGTGCCTCTCTTCAGTCATTC
MYH3 CCGAGGAGGCTGATGAACAA CGCTCACTCTTCGCTCTCAT
MYOD1 GCAAGCGCAAGACCACTAAC GGCTTCGTTGACTTTGCTCA
MYF5 TGTTCAGAGCCCACTAGCC GGTGATCCGATCCACTATGC
MYF6 CTCGTGATAACCGCCAAGGA CGATGGAAGAAAGGCATCGA
Human MYOD1 CCGACGGCATGATGGACTAC AGGCAGTCTAGGCTCGACAC
MYOCYTES FROM EQUINE IPSCS 3
LIF before transduction with LV-TRE-WT human MyoD-
T2A-dsRedExpress2 (Fig. 1B). One day after adding doxycy-
cline, we could observe red-fluorescent cells (Fig. 1C) that
followed a few days later by formation of myotubes that
stained for MyHC (Fig. 1D–G). We used this strategy with two
different iPSC lines, H and U, although with variable efficiency
and were able to maintain these myotubes in culture without
detaching or other signs of cell death for at least 7 days, even
after doxycycline had been removed.
Characteristics of myotubes derived
from equine iPSCs
To characterize myotubes obtained from iPSC-derived
mesenchymal cells (hereafter referred to as iPSC myotubes),
we compared their properties with those of myotubes gen-
erated spontaneously from progenitor cell cultures obtained
from adult equine muscle (muscle progenitor cells [MPC]
myotubes, Fig. 1H). iPSC myotubes were smaller than MPC
myotubes, as indicated by smaller mean areas, particularly
in the case of U-line myotubes, and smaller mean numbers
of myonuclei per myotube (only statistically significant for
U-line myotubes, Fig. 2A).
To investigate the developmental stage of iPSC compared
with MPC myotubes, we performed qPCR analyses of se-
lected genes (Fig. 2B), including embryonic (MYH3) and
adult (MYH1, MYH2) MyHC isoforms, as well as MYF5,
MYOD1, and MYF6 (also known as MRF4), three myogenic
regulatory factors (MRFs) that are temporally expressed in
this order during fetal myogenesis (Bentzinger et al., 2012).
Compared with MPC myotubes, iPSC myotubes expressed
MYH3 and MYH2, but notMYH1, an isoform that is naturally
expressed at a relatively late stage (late fetal or postnatal)
during normal muscle development (Schiaffino et al., 2015).
Expression ofMYH2 andMYH3 by iPSC line Hmyotubes was
similar ( p> 0.1) to that by MPC myotubes, but was compar-
atively lower ( p< 0.05) in iPSC line U myotubes.
Moreover, consistent with their reduced size and lack of
expression of mature MYH isoform, the expression of
MYOD1 and MYF6 by iPSC myotubes was in general much
lower than by MPC myotubes, suggesting only partial acti-
vation of the myogenic transcriptional program in response to
FIG. 1. Representative micrographs of equine iPSCs before (A) and after (B) differentiation for 14 days in 10% FBS, at
which point, cells were transduced with the LV-TRE-WT human MyoD-T2A-dsRedExpress2 construct followed by pu-
romycin selection. Treatment of selected cells with doxycycline resulted in the appearance of red fluorescent cells within 1
day (C) and the formation of abundant myotubes (D) that stained positive for MyHC (E). Myotubes generated from iPSC
lines H (D–F) and U (G, which displayed only mild MyHC staining) were compared to those generated from adult MPCs
(H). Green =MyHC, blue =DAPI. Scale bar: 50lm. iPSC, induced pluripotent stem cell; MyHC, myosin heavy chain;
MPCs, muscle progenitor cells. Color images available online at www.liebertpub.com/cell
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FIG. 2. Characteristics of myotube cultures generated from equine iPSC lines H and U, and from adult MPCs in
relationship to (A) myotube area and number of myonuclei (n= 16 myotubes per cell type) and (B) transcript levels
(normalized to 18S) of MyHC isoforms (MYH1, MYH2, and MYH3) and myogenic regulatory factors (MYOD, MYF6, and
MYF5, n = 3 independent cultures per cell type). Undiff iPSCs, undifferentiated parental iPSCs. Values are shown as
mean – SE. Means with different superscripts (a–c) are different ( p < 0.05). n.d, not detected; SE, standard error.
5
ectopicMyoD expression in iPSC-derived cells.MYF5was not
detected in myotubes from any of the two iPSC lines. This is
the first MRF to be expressed during muscle development in
the embryo, although it has been shown to be functionally
redundant with the downstream gene, MyoD, so that in the
absence of Myf5, myogenesis can proceed normally once
MyoD has been activated (Bentzinger et al., 2012). Consistent
with this, activation of endogenous Myf5 was not required for
myogenesis to occur in response to ectopic MyoD in our study.
Overall, the reduced myogenic response from U- compared
with H-line iPSCs may reflect intrinsic differences in their
epigenetic landscape imposed during reprogramming, and
may also have been resulted, at least in part, from mean lower
relative expression (although not statistically significant) of
the virus-driven human MyoD transgene in U compared with
H cells (3.6-fold lower, p= 0.06, n= 3 experiments).
Finally, we assessed the electrophysiological properties
of the myotubes generated in vitro by measuring intracel-
lular calcium release in response to KCl-induced membrane
depolarization, which is a measure of functional coupling be-
tween plasma membrane voltage-dependent calcium channels
and calcium release from the sarcoplasmic reticulum mem-
brane of skeletal muscle cells. A calcium response was elicited
by membrane depolarization of iPSC myotubes as it was
from MPC myotubes (Fig. 3), indicating a degree of elec-
trophysiological maturation in iPSC myotubes and in
agreement with previous data with human iPSCs (Skoglund
et al., 2014).
In conclusion, this is the first report of the generation of
functional muscle cells from equine iPSCs, as indicated by
the ability of myotubes to respond to a membrane depo-
larization stimuli. Compared with myotubes generated from
adult MPCs, iPSC-derived myotubes displayed an immature
phenotype and could thus be particularly useful for develop-
mental and disease pathogenesis studies. Further work should
be aimed at optimizing protocols for induction of myogenesis
from iPSCs of equine and other large animal species using
gene-free strategies, an approach that may lead to the gener-
ation of fully mature myotubes in vitro.
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FIG. 3. (A) Calcium responses (expressed
as mean –SE change in Fluo-4 intensity) to
depolarization with 75mM KCl of myotubes
derived from iPSCs (line H) or adult MPCs
(both shown as black bars) and undifferen-
tiated iPS-derived cells or MPCs (shown by
white bars, n = 5–6 myotubes per cell type).
Means with different superscripts (a, b) are
different ( p < 0.05). (B) Representative mi-
crographs showing changes in fluorescence
before (upper panels) and 1 minute after
(lower panels) addition of 75mM KCl to
iPSC- or MPC myotube cultures. Scale bar:
50 lm. Color images available online at
www.liebertpub.com/cell
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